Summit Therapeutics PLC (NASDAQ:SMMT - Get Free Report) shares reached a new 52-week low on Monday. The stock traded as low as $12.01 and last traded at $12.6040, with a volume of 1,698,713 shares traded. The stock had previously closed at $14.15.
Trending Headlines about Summit Therapeutics
Investors following SMMT have been watching these headlines:
Analysts Set New Price Targets
Several brokerages recently issued reports on SMMT. The Goldman Sachs Group set a $41.00 price target on shares of Summit Therapeutics and gave the company a "buy" rating in a report on Tuesday, September 29th. Morgan Stanley cut shares of Summit Therapeutics to an "outperform" rating in a research note on Tuesday, September 29th. Wall Street Zen raised shares of Summit Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, September 5th. UBS Group reaffirmed a "neutral" rating on shares of Summit Therapeutics in a report on Wednesday, September 23rd. Finally, HC Wainwright reiterated a "buy" rating on shares of Summit Therapeutics in a research note on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Summit Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $28.61.
Get Our Latest Analysis on Summit Therapeutics
Summit Therapeutics Trading Down 9.1%
The firm has a fifty day simple moving average of $16.41 and a 200-day simple moving average of $16.14. The stock has a market cap of $10.28 billion, a price-to-earnings ratio of -11.99 and a beta of -1.49.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in shares of Summit Therapeutics during the 2nd quarter worth approximately $138,838,000. Candriam S.C.A. lifted its holdings in Summit Therapeutics by 212.3% in the third quarter. Candriam S.C.A. now owns 1,662,969 shares of the company's stock valued at $28,224,000 after buying an additional 1,130,537 shares during the period. Bank of America Corp DE acquired a new position in Summit Therapeutics in the second quarter valued at approximately $12,603,000. The Manufacturers Life Insurance Company lifted its holdings in Summit Therapeutics by 34.4% in the first quarter. The Manufacturers Life Insurance Company now owns 592,810 shares of the company's stock valued at $11,240,000 after buying an additional 151,857 shares during the period. Finally, Simplify Asset Management Inc. bought a new position in Summit Therapeutics in the third quarter valued at approximately $8,626,000. 4.61% of the stock is currently owned by institutional investors and hedge funds.
Summit Therapeutics Company Profile
(
Get Free Report)
Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its lead candidate is ivonescimab, a bispecific antibody designed to target both PD-1 and VEGF, two pathways involved in tumor growth and the immune response. The company is evaluating the treatment in clinical trials for multiple types of cancer. Summit licensed rights to develop and commercialize ivonescimab from China-based Akeso in 2022. Summit's licensed territory covers markets outside China, including the United States, Canada, Europe and Japan.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Summit Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Summit Therapeutics wasn't on the list.
While Summit Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.